SUMMARY
INTRODUCTION
Wound healing is characterized by complex changes at the inter-and intracellular level, including inflam mation, cell migration, and proliferation and reconstruc tion of the extracellular matrix (ECM).1' 6 One of the ECM molecules whose expression is altered during wound healing is tenascin (TN-C).2,3,7~!2 This large hexameric glycoprotein was first detected in developing embryos, where it was found predominantly at epithelial-mesenchymal interaction sites.13"17 In adult tissues, expression of tenascin is rather limited. In nor mal human skin, tenascin is present in the papillary dermis and near the basement membranes surrounding blood vessels and epidermal adnexa. 12, 18, 19 We and others have shown that the expression of tenascin in the papillary dermis of normal skin varies from almost absent to a patchwise distribution underneath the basement membrane, but is strongly upregulated in conditions of epidermal hyperproliferation such as psoriasis,18 epidermal tumours, 21 and injury. 3, 9, 22 Although in vitro studies have suggested various func tions for tenascin, including modulation of cell adhesion23-28 and the immune response,29,30 its in vivo role is still a matter of debate. 31 Tenascin expression during wound healing has been studied in various animal models. data on wound healing in humans, however, are quite limited: tenascin expression was studied previously in surgical wounds,9 chronic venous ulcers,32 and in the tape-stripping model for epidermal injury. 22 On the basis of the findings, it was postulated that tenascin might stimulate keratinocyte migration2,7,8,10 and that tenascin expression correlates with epidermal proliferation.10, 22 We now provide new immunohistochemical data on the pattern and kinetics of tenascin expression in human skin wounds. Experimental excisional wounding of nor mal human skin was performed to obtain standardized wounds. This experimental set-up allowed the compari son of tenascin expression at various stages of wound healing in the same subject. Tenascin expression in the excisional wounds was compared with expression in explant cultures of normal human skin. These explants are useful as a model for some aspects of normal wound healing, including keratinocyte migration. In addition, tenascin expression was investigated in chronic venous ulcers, which represent inadequately healing wounds. In parallel with the tenascin staining, immunostaining of proliferation markers was performed to see whether tenascin expression correlates with keratinocyte prolif eration, as we suggested previously for hyperprolifera tive skin disorders and the tape-stripping model. 22 Finally, heparan sulphate and laminin, two major com ponents of basement membranes, were stained to estab lish whether during wound healing keratinocytes are separated from dermal tenascin by a complete basement membrane, as in normal intact skin. • / / / / w ' s , ;
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IlllliltBiSl. : ; "llMiÜÉiiil. keratinocytes stained positive for both proliferation markers. In all excisional wounds and ulcers, but not in the explants, proliferating cells were markedly increased compared with normal skin. With respect to the excisional wounds, the staining results can be described as follows. At days 2,4, and 7, proliferating keratinocytes were rarely detected in the neo-epidermis but mainly at some distance from the wound margins. An area with almost 100 per cent proliferating keratinocytes was located approxi mately 10-15 cells away from the leading edge at day 2 . This intervening area of 10-15 cells contained about 20 per cent proliferating cells. The flattened cells of the leading edge itself were never Ki-67-or PCNA-positive. At days 4 and 7 after wounding, an area with almost 100 per cent proliferating keratinocytes was separated by some 50 cells from the leading edge of migrating keratinocytes. Of these 50 cells, approximately 20 per cent stained positive. When the wounds were closed, at day 7 or 14, hyperproliferation at these sites was less pro nounced. Basal keratinocytes directly adjacent to the former wound margins and in the newly formed epidermis had become proliferative instead (Fig. 2b) .
In the skin explants, prolifer^ig^rsies; did not alter markedly during the 4-day^cultufe period. No PCNApositive cells could be detected in the explants and fewer than 5 per cent of the basal cells stained positive for the Ki-67 antigen.
In the sections of chronic venous ulcers, PCNA-and Ki-67-positive cells were abundant in the basal layers of the neo-epidermis and the adjacent epidermis. Consist ent with our findings concerning the excisional wound model, hyperproliferative areas with 75-100 per cent PCNA-or Ki-67-positive keratinocytes were seen at some distance from the ulcer edges, typically 50-150 basal keratinocytes away. In this area, 20-50 per cent of the basal keratinocytes were Ki-67-or PCNA-positive, (not shown).
Basal membrane staining
Heparan sulphate and laminin were stained to address the question of whether keratinocytes are separated from dermal tenascin by an intact basement membrane during wound healing. Positive staining for heparan sulphate was found in the basement membranes of normal skin before and after explant culture, and in intact skin adjacent to the excisional wounds and the ulcers. Remarkably, heparan sulphate staining ceased abruptly at the margins of the wounds and the cultured biopsies and was never detected under the neo-epidermis at any time in any of the models used (Fig. 3b) .
The staining pattern of laminin was similar to that of heparan sulphate in normal skin and in all the explants, but only up to 4 days after wounding in the excisional wounds. Seven days after wounding in half of the excisional wounds, laminin was detectable beneath the migrated keratinocytes near the wound margins, but not beneath the leading edge of migrated keratinocytes; in the other excisional wounds of day 7, laminin staining still resembled heparan sulphate staining. In the 14-dayold excisional wounds, laminin was found beneath the entire neo-epidermis of all biopsies (Fig. 3c) .
In one of five ulcers, the staining pattern of laminin resembled that of heparan sulphate. In the other four ulcers studied, laminin was detected beneath the entire neo-epidermis.
DISCUSSION
We investigated tenascin expression during normal and pathological wound healing in vivo and in an in vitro model for keratinocyte migration using skin explant culturing. The results indicate that tenascin is markedly upregulated under all these conditions, but with different patterns and kinetics of upregulation. Tenascin is discontinuously distributed near the basement membrane in the papillary dermis of normal skin. In contrast, in the papillary dermis bordering excisional wounds and ulcers, or in the papillary dermis of the original biopsies that were used for explant culturing, tenascin continu ously lined the basement membrane and to a variable extent penetrated more deeply into the dermis. In the dermal parts that were covered by migrated keratino cytes during wound healing or explant culturing, tenascin was clearly detected in all ulcers and explants, but only after wound closure in the excisional wounds. These data indicate that in chronic venous ulcers, where the normal coordination of the wound-healing process is lost* the induction of tenascin expression in the wound bed does not depend on keratinocyte migration and subsequent wound closure. Downregulation of tenascin protein to normal levels was not seen in our dynamic models, either in excisional wounds that were already covered by a multilayered neo-epidermis or in the explants in which keratinocytes had enclosed the dermal part of the cultured biopsies. This may be due to continued production of tenascin or to slow turnover of pre-existing tenascin.
A prerequisite for tenascin having a direct in vivo effect on keratinocytes, whether it concerns an influence on migration, proliferation, or other cellular activities, is that keratinocytes can directly interact with tenascin in the dermis. In normal intact skin, the basement mem brane at the dermal-epidermal junction precludes con tact between keratinocytes and tenascin: the size of the hexameric tenascin molecules, which in humans is approximately 19 00 kD,34 prevents them from moving to the epidermis by diffusion. In this study we have shown that during the later stages of normal wound healing, tenascin is expressed diffusely in the wound bed and that at the same time no heparan sulphate is detectable beneath the neo-epidermis covering the wound bed. We speculate that in these conditions, keratinocytes in the neo-epidermis may interact directly with tenascin because no complete basement membrane is present. These histological data, however, cannot exclude the possibility that a provisional basement mem brane, containing laminin and possibly other basement membrane components,35 hampers interaction between keratinocytes and tenascin. Further studies using immunoelectron microscopic analysis of the dermalepidermal junction structures are mandatory to obtain more conclusive answers.
Others have suggested previously that during wound healing, keratinocytes migrate over a surface rich in tenascin.8 According to our data, tenascin is not a substrate for migrating keratinocytes: keratinocyte migration precedes tenascin expression both in excisional wounds and in skin explants.
Our hypothesis that tenascin upregulation correlates with keratinocyte proliferation was partially confirmed by the results of this study: at the borders of excisional wounds and chronic venous ulcers, tenascin was mark edly upregulated in the dermis beneath epidermal hyperproliferative areas. Because at these borders a basement membrane is present that separates proliferative kerati nocytes from dermal tenascin, a mitogenic effect of tenascin in this is not likely. Hyperproliferative kerati nocytes, however, may produce a factor that induces tenascin expression in the underlying dermis. Candidates are the growth factors interleukin-1 (IL-1), tumour necrosis factor-a (TNFa), and transforming growth factor-/? (TGFyS), which in vitro stimulate tenascin pro duction by cultured fibroblasts.36,37 Other aspects of cytokine action in wound healing are dealt with at length in the review by Slavin in this issue of the journal.38 Proliferation of keratinocytes, however, appears not to be a prerequisite for tenascin upregulation in our in vitro model; in the explants, tenascin was clearly upregulated, although very few proliferating cells were detected. Likewise, inflammation cannot be mandatory for tenascin upregulation during explant culture, as the explants are excluded from influx of inflammatory cells from the blood. Further studies should be directed at identifying keratinocyte-derived and other possible factors that may regulate dermal tenascin expression during wound healing.
